Armonair Respiclick Patent Expiration

Armonair Respiclick is a drug owned by Teva Pharmaceutical Industries Ltd. It is protected by 35 US drug patents filed from 2017 to 2024. Out of these, 26 drug patents are active and 9 have expired. Based on its patents and exclusivities, its generic launch date is estimated to be Feb 20, 2040. Details of Armonair Respiclick's patents and their expiration are given in the table below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11969544

(Pediatric)

Inhalers and airflow adaptors therefor
Feb, 2040

(15 years from now)

Active
US11969544 Inhalers and airflow adaptors therefor
Aug, 2039

(14 years from now)

Active
US10918816 Compliance monitoring module for a breath-actuated inhaler
Dec, 2035

(11 years from now)

Active
US8714149

(Pediatric)

Airflow adaptor for a breath-actuated dry powder inhaler
Aug, 2032

(7 years from now)

Active
US8978966

(Pediatric)

Dose counters for inhalers, inhalers and methods of assembly thereof
Jul, 2032

(7 years from now)

Active
US10561808

(Pediatric)

Dose counter for inhaler having an anti-reverse rotation actuator
Jul, 2032

(7 years from now)

Active
US8714149 Airflow adaptor for a breath-actuated dry powder inhaler
Feb, 2032

(7 years from now)

Active
US8978966 Dose counters for inhalers, inhalers and methods of assembly thereof
Jan, 2032

(7 years from now)

Active
US10561808 Dose counter for inhaler having an anti-reverse rotation actuator
Jan, 2032

(7 years from now)

Active
US9216260

(Pediatric)

Dose counters for inhalers, inhalers and methods of assembly thereof
Dec, 2031

(7 years from now)

Active
US10124131

(Pediatric)

Dose counter for inhaler having an anti-reverse rotation actuator
Nov, 2031

(7 years from now)

Active
US9731087

(Pediatric)

Dose counter for inhaler having a bore and shaft arrangement
Nov, 2031

(7 years from now)

Active
US10022510

(Pediatric)

Dose counters for inhalers, inhalers and methods of assembly thereof
Nov, 2031

(7 years from now)

Active
US10195375

(Pediatric)

Airflow adaptor for a breath-actuated dry powder inhaler
Aug, 2031

(6 years from now)

Active
US9216260 Dose counters for inhalers, inhalers and methods of assembly thereof
Jun, 2031

(6 years from now)

Active
US10022510 Dose counters for inhalers, inhalers and methods of assembly thereof
May, 2031

(6 years from now)

Active
US10124131 Dose counter for inhaler having an anti-reverse rotation actuator
May, 2031

(6 years from now)

Active
US9731087 Dose counter for inhaler having a bore and shaft arrangement
May, 2031

(6 years from now)

Active
US10195375 Airflow adaptor for a breath-actuated dry powder inhaler
Feb, 2031

(6 years from now)

Active
US8651103

(Pediatric)

Dry powder inhalation apparatus
Sep, 2028

(3 years from now)

Active
US8651103 Dry powder inhalation apparatus
Mar, 2028

(3 years from now)

Active
US9463288

(Pediatric)

Dry powder inhalation apparatus
Nov, 2025

(1 year, 1 month from now)

Active
US10765820

(Pediatric)

Dry powder inhalation apparatus
Nov, 2025

(1 year, 1 month from now)

Active
US10765820 Dry powder inhalation apparatus
May, 2025

(7 months from now)

Active
US9463288 Dry powder inhalation apparatus
May, 2025

(7 months from now)

Active
US9616024

(Pediatric)

Process for preparing a medicament
Mar, 2025

(4 months from now)

Active
US9616024 Process for preparing a medicament
Sep, 2024

(a month ago)

Expired
US7540282

(Pediatric)

Reservoir pressure system for medicament inhaler
Nov, 2023

(10 months ago)

Expired
US7540282 Reservoir pressure system for medicament inhaler
May, 2023

(1 year, 4 months ago)

Expired
US6748947 De-agglomerator for breath-actuated dry powder inhaler
Jun, 2021

(3 years ago)

Expired
US6718972 Dose metering system for medicament inhaler
Jun, 2021

(3 years ago)

Expired
US6871646 De-agglomerator for breath-actuated dry powder inhaler
Jun, 2021

(3 years ago)

Expired
US8006690 Reservoir pressure system for medicament inhaler
Jun, 2021

(3 years ago)

Expired
US6701917 Dose counter for medicament inhaler
Jun, 2021

(3 years ago)

Expired
US6446627 Inhaler dose counter
Dec, 2017

(6 years ago)

Expired


A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Armonair Respiclick's patents.

Given below is the list of recent legal activities going on the following patents of Armonair Respiclick.

Activity Date Patent Number
Patent litigations
Payment of Maintenance Fee, 8th Year, Large Entity 21 Mar, 2024 US9463288
Payment of Maintenance Fee, 4th Year, Large Entity 21 Feb, 2024 US10765820
Expire Patent 02 Oct, 2023 US8006690
Payment of Maintenance Fee, 4th Year, Large Entity 20 Jul, 2023 US10561808
Payment of Maintenance Fee, 8th Year, Large Entity 23 May, 2023 US9216260
Maintenance Fee Reminder Mailed 19 Apr, 2023 US8006690
Payment of Maintenance Fee, 8th Year, Large Entity 08 Sep, 2022 US8978966
Payment of Maintenance Fee, 4th Year, Large Entity 27 Jul, 2022 US10195375
Payment of Maintenance Fee, 4th Year, Large Entity 04 May, 2022 US10124131
Payment of Maintenance Fee, 4th Year, Large Entity 14 Jan, 2022 US10022510


While patent expiration is one way of estimating the generic date of a drug, if a patent gets invalidated somehow, the generic of the drug may arrive early. Being aware of all relevant patents can help in avoiding legal pitfalls. Given below are details of the litigation history of Armonair Respiclick and ongoing litigations to help you estimate the early arrival of Armonair Respiclick generic.

Armonair Respiclick's Litigations

Armonair Respiclick been subject to various legal proceedings, including patent litigations. The earliest legal proceeding was initiated on Oct 26, 2018, against patent number US10561808. The petitioner , challenged the validity of this patent, with Declan Walsh et al. as the respondent. Click below to track the latest information on how companies are challenging Armonair Respiclick's patents.

Last updated on October 1, 2024
Patent Proceeding Filing Date Status Respondent Petitioner
Patent litigations
US10561808 October, 2018 Decision
(20 Sep, 2019)
Declan Walsh et al.


FDA has granted some exclusivities to Armonair Respiclick. Till the time these exclusivities are active, no other company can market a generic or bioequivalent version of Armonair Respiclick, regardless of the status of it's patents. These exclusivities hence play a crucial role in delaying the generic launch. Given below are details of the exclusivities granted to Armonair Respiclick.

Exclusivity Information

Armonair Respiclick holds 4 exclusivities out of which 3 have expired. Its last outstanding exclusivity is set to expire in 2025. Details of Armonair Respiclick's exclusivity codes and their expiration dates are given below.


Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Jan 27, 2020
New Patient Population(NPP) Jul 09, 2024
New Strength(NS) Jul 09, 2024
Pediatric Exclusivity(PED) Jan 09, 2025

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

Several oppositions have been filed on Armonair Respiclick's European patents. EP oppositions can significantly impact the timeline for the generic launch of drugs. If an opposition results in the revocation or amendment of a patent, it can shorten the exclusivity period of the original drug. This can lead to an earlier entry of generic versions into the market. To help you estimate the potential early arrival of Armonair Respiclick's generic, the next section provides detailed information on ongoing and past EP oppositions related to Armonair Respiclick patents.

Armonair Respiclick's Oppositions Filed in EPO

Armonair Respiclick has faced multiple oppositions in the European Patent Office. The earliest opposition was filed on Sep 03, 2009, by Vectura Delivery Devices Limited. This opposition was filed on patent number EP01948660A. Click below to reveal the latest opposition data.


Application Filing Date Opposition Party Legal Status
Patent litigations
EP19155324A Jun, 2021 Vectura Limited Granted and Under Opposition
EP04782768A Apr, 2015 AstraZeneca Pharma Poland Sp. z.o.o. Revoked
EP01948660A Aug, 2014 Hexal Aktiengesellschaft Patent maintained as amended
EP04782768A Nov, 2011 Vectura Limited Revoked
EP04782768A Nov, 2011 AstraZeneca AB Revoked
EP01948660A Sep, 2009 Vectura Delivery Devices Limited Patent maintained as amended


US patents provide insights into the exclusivity only within the United States, but Armonair Respiclick is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Armonair Respiclick's family patents as well as insights into ongoing legal events on those patents.

Armonair Respiclick's Family Patents

Armonair Respiclick has patent protection in a total of 34 countries. It's US patent count contributes only to 16.4% of its total global patent coverage. 7 countries have all of their patents expired or invalidated which has opened up potential generic launch opportunities in these countries. Click below to unlock the full patent family tree for Armonair Respiclick.

Family Patents

Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List


Generic Launch

Generic Release Date:

Armonair Respiclick's generic launch date based on the last expiry date of its patents and exclusivities combined is estimated to be Feb 20, 2040 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)

Armonair Respiclick Generics:

Fluticasone Propionate is the generic name for the brand Armonair Respiclick. 13 different companies have already filed for the generic of Armonair Respiclick, with Hikma having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Armonair Respiclick's generic

Alternative Brands for Armonair Respiclick

There are several other brand drugs using the same active ingredient (Fluticasone Propionate) as Armonair Respiclick. Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.


Apart from brand drugs containing the same ingredient, some generics have also been filed for Fluticasone Propionate, Armonair Respiclick's active ingredient. Check the complete list of approved generic manufacturers for Armonair Respiclick





About Armonair Respiclick

Armonair Respiclick is a drug owned by Teva Pharmaceutical Industries Ltd. Armonair Respiclick uses Fluticasone Propionate as an active ingredient. Armonair Respiclick was launched by Teva Pharm in 2022.

Approval Date:

Armonair Respiclick was approved by FDA for market use on 08 April, 2022.

Active Ingredient:

Armonair Respiclick uses Fluticasone Propionate as the active ingredient. Check out other Drugs and Companies using Fluticasone Propionate ingredient

Dosage:

Armonair Respiclick is available in powder form for inhalation use. Given below is detailed information on Dosage -

Strength Dosage Form Availability Application Pathway
0.055MG/INH POWDER Discontinued INHALATION
0.03MG/INH POWDER Discontinued INHALATION
0.232MG/INH POWDER Discontinued INHALATION
0.113MG/INH POWDER Discontinued INHALATION